Arvinas, Inc.
ARVN
Jodie situation report
Arvinas, Inc.'s move is spreading beyond its market group.
No new filing conclusion is available. 23 of 23 group members are active now; 1 filing-linked outsider is moving with the group, and 0 of 6 directly disclosed connections are confirming.
- At least 15 of 23 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- BMRN remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 8 of 23 members or fewer.
Who this business touches
The relationships behind ARVN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
PFEPfizer, Inc.partnerMay 11, 2026 ▾
“In September 2025, we and Pfizer, Inc.”
NVSNovartis AGinvesteeMay 11, 2026 ▾
“In the second quarter of 2024, we completed a transaction with Novartis Pharma AG, or Novartis, which comprised a license agreement, or the Novartis License Agreement, and an asset agreement, or the Novartis Asset Agreement.”
Depended on by
PFEPfizer, Inc.partnerMay 5, 2026 ▾
“37 Approvals: PRODUCT INDICATION DATE/MARKET Veppanu (vepdegestrant) (a) Treatment of adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endo…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 6 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ARVN is currently a Participant in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.